Gennisium Pharma

Gennisium Pharma is a French pharmaceutical company dedicated to the development and commercialization of innovative medicines for neonates and pediatric patients. The company focuses on addressing significant unmet medical needs in neonatal intensive care units (NICUs) by reformulating established molecules for safer and more effective use in newborns. Their portfolio includes treatments for conditions such as apnea of prematurity and persistent pulmonary hypertension of the newborn. Gennisium leverages its expertise in pediatric drug development to navigate complex regulatory pathways, including Pediatric Use Marketing Authorizations (PUMA) in Europe. By providing age-appropriate formulations, the company aims to improve clinical outcomes for the most vulnerable patient populations.